Table 1 lists the representative ClpP agonists, their activities against tumor cells, pharmacological effects, among which Imipridone-class compounds represented by ONC201 have advanced to phase III clinical trials and demonstrated excellent antitumor effects. Here, CLPP is linked to neoplasm.